Nimodipine

Generic Name: Nimodipine

Brand Names: Nimotop, Nymalize

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆N_₂O_₇

CAS Number: 66085-59-4

Unique Ingredient Identifier: 57WA9QZ5WH

Background: Nimodipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nimodipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation. Nimodipine is used to as an adjunct to improve the neurologic outcome following subarachnoid hemorrhage from ruptured intracranial aneurysm.

Indication: For use as an adjunct to improve neurologic outcome following subarachnoid hemorrhage (SAH) from ruptured intracranial berry aneurysms by reducing the incidence and severity of ischemic deficits.

Associated Conditions: Delayed Ischemic Neurological Deficit

Clinical Trials

Effectiveness of Calcium Channel Blockade for OP and Carbamate Pesticide Poisoning

Phase 3

Active, not recruiting

Conditions: Pesticide Poisoning
Anticholinesterase Insecticide Poisoning

Interventions: Drug: Magnesium Sulfate
Drug: Nimodipine

First Posted Date: 2019-04-23

Last Posted Date: 2025-02-28

Lead Sponsor: University of Edinburgh

Target Recruit Count: 3243

Registration Number: NCT03925025

Locations: 🇧🇩
Chattogram Medical College Hospital, Chittagong, Bangladesh
🇧🇩
Jashore Medical College Hospital, Jessore, Bangladesh
🇧🇩
Shaheed Ziaur Rahman Medical College, Bogra, Silimpur, Bangladesh

and more 4 locations

Bioavailability Comparison Study of Two Types of Nimodipine Injections in Healthy Volunteers

Early Phase 1

Conditions: Bioavailability
Ischemic Cerebrovascular Disease
Safety Issues

Interventions: Drug: Nimodipine Injection
Drug: Nimodipine Injection (II)

First Posted Date: 2019-01-07

Last Posted Date: 2019-01-08

Lead Sponsor: Shenyang Dongxing Pharmaceutical Technology Co., Ltd.

Target Recruit Count: 26

Registration Number: NCT03794843

Locations: 🇨🇳
Xuanwu Hospital Capital Medical University, Beijing, Beijing, China

Cognitive Effects of Nimodipine in Patients With Schizophrenia

Early Phase 1

Completed

Conditions: Schizophrenia
Schizo Affective Disorder

Interventions: Drug: Placebo oral capsule
Drug: Nimodipine

First Posted Date: 2018-09-14

Last Posted Date: 2023-06-23

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 18

Registration Number: NCT03671525

Locations: 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

RCVS: The Rational Approach to Diagnosis and Treatment

Phase 4

Withdrawn

Conditions: Reversible Cerebral Vasoconstriction Syndrome

Interventions: Diagnostic Test: TCD- cerebral blood flow velocities
Behavioral: Headache pain score
Other: Neurological examination
Diagnostic Test: Repeat Neuroimaging
Drug: Verapamil ER
Drug: Nimodipine

First Posted Date: 2017-05-12

Last Posted Date: 2019-09-18

Lead Sponsor: Johns Hopkins University

Registration Number: NCT03150524

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Noninvasive Assessment of Cerebral Oxygenation and Cardiac Function in Patients With Neurovascular Diseases

Completed

Conditions: Subarachnoid Hemorrhage, Aneurysmal

First Posted Date: 2016-12-13

Last Posted Date: 2019-03-26

Lead Sponsor: National Institute of Mental Health and Neuro Sciences, India

Target Recruit Count: 25

Registration Number: NCT02991157

Locations: 🇮🇳
NIMHANS, Bengaluru, India

Safety/Pharmacokinetic Study Comparing Intracisternal EG-1962 to Standard of Care Enteral Nimodipine in Adults With aSAH

Phase 1

Terminated

Conditions: Subarachnoid Hemorrhage, Aneurysmal

Interventions: Drug: EG-1962 (nimodipine microparticles)
Drug: Enteral Nimodipine

First Posted Date: 2016-09-09

Last Posted Date: 2018-07-26

Lead Sponsor: Edge Therapeutics Inc

Target Recruit Count: 6

Registration Number: NCT02893826

Locations: 🇨🇦
University of Alberta Hospital/Mackenzie Health Sciences Centre, Edmonton, Alberta, Canada
🇺🇸
Dignity Health; St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸
University of California San Francisco, San Francisco, California, United States

and more 1 locations

Study of EG-1962 Compared to Standard of Care Oral Nimodipine in Adults With Aneurysmal Subarachnoid Hemorrhage

Phase 3

Terminated

Conditions: Subarachnoid Hemorrhage, Aneurysmal

Interventions: Drug: Enteral Nimodipine
Drug: EG-1962 (nimodipine microparticles)

First Posted Date: 2016-06-06

Last Posted Date: 2018-07-26

Lead Sponsor: Edge Therapeutics Inc

Target Recruit Count: 374

Registration Number: NCT02790632

Locations: 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
🇺🇸
UCSF, San Francisco, California, United States
🇦🇹
Medizinische Universitat Innsbruck/Tirol Universitatsklinik fur Neurologie, Innsbruck, Austria

and more 76 locations